News|Podcasts|November 16, 2026

The Ron Lanton Report: Ossium Health's Bone Marrow Bank

Ossium Health’s Kevin Caldwell joins The Ron Lanton Report to explain how banked, deceased-donor marrow is replacing a months-long search for a living donor with a product hospitals can order on demand.

In this episode of The Ron Lanton Report, Kevin Caldwell, CEO, co-founder, and president of Ossium Health, joins Ron Lanton, senior partner, Lanton, Lanton & Sosa Law PLLC, to describe how his company is rebuilding the bone marrow transplant process around deceased organ donors rather than living volunteers.

In his conversation with Lanton, Caldwell explains that traditional transplants depend on finding, testing, and consenting a living donor, a process that can take months while a patient’s disease progresses, and one that sometimes fails outright if a match becomes unavailable or a patient deteriorates first. Ossium’s alternative draws on the same deceased organ donor population used for solid organ transplants for decades, recovering far more cells per donor than could ever ethically be taken from a living person, then cryopreserving and banking that marrow for on-demand use.

Caldwell frames the company’s work as combining pieces of science that have existed for decades and dramatically improving each one: Ossium’s recovery process yields roughly three times the cells of prior methods with double the sterility success, while cryopreservation techniques developed by Erik Woods, CSO, co-founder & executive vice president, retain more than 90% of cells post-thaw, compared to roughly half lost under older methods. The result is a product that can reach a transplant center in as little as 31 hours, versus a standard of care of 12 to 15 weeks.

Caldwell also details how physician adoption began cautiously in 2023 before accelerating sharply after the first deceased-donor marrow transplant for blood cancer was performed in 2024 at Henry Ford Transplant Center by Dr. Munir Abidi, with strong, swift engraftment and no serious adverse events. The initial planned 12-patient study is now fully enrolled and Ossium is continuing to treat patients under an expanded access program, with transplants happening roughly once per week.

Looking ahead, Caldwell identifies physician education and operational scaling such as scaling from roughly three donors processed per day to a potential 20 domestically and more than 100 globally, as the next hurdles to widespread use. He closes the discussion by emphasizing that Ossium’s ultimate goal is to remove donor availability as a variable entirely, letting physicians and patients make treatment decisions on their own timeline rather than a donor’s.


Related to this article

Pharmaceutical Executive Daily
FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.
Pharmaceutical Executive Daily
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.